تعديل

jeudi 14 avril 2016

Repros to drop testosterone drug in U.S. if key study fails

(Reuters) - Repros Therapeutics Inc will abandon efforts to seek approval for its testosterone drug in the United States if an ongoing study fails, and shift focus to its uterine fibroids drug that showed promise in a mid-stage trial.


http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro

Aucun commentaire:

Enregistrer un commentaire